APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vaccine Adjuvants

An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.

Selected research

Market Structure

Global Vaccine Adjuvants Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174044770325 December 2025199 pages

Choose your research edition.

Industry ResearchVaccine Adjuvants Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaccine Adjuvants Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Vaccine Adjuvants Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaccine Adjuvants Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaccine Adjuvants Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.

The top 5 global manufacturers of vaccine adjuvants are GSK, CSL Limited, Croda, SEPPIC, Novavax, which have a combined market share of about 55 percent. North America is the largest market, with a share about 38%, followed by Europe and Asia Pacific with the share about 27% and 22%.

This report provides an overview of the global Vaccine Adjuvants market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Vaccine Adjuvants and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vaccine Adjuvants sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vaccine Adjuvants market size, projected growth trends, production technologies, key applications, and end-use industries.

Vaccine Adjuvants Segment by Company

GSK

CSL Limited

Croda

SEPPIC

Novavax

SPI Pharma

Phibro

SDA BIO

Invivogen

Tj Kaiwei

OZ Biosciences

Brenntag Biosector

MVP Laboratories

Zhuoyue

Aphios

Vaccine Adjuvants Segment by Type

Aluminum Adjuvant

Emulsions Adjuvant

Others

Vaccine Adjuvants Segment by Application

Human Vaccine

Veterinary Vaccine

Vaccine Adjuvants Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine Adjuvants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaccine Adjuvants and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine Adjuvants.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vaccine Adjuvants market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vaccine Adjuvants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Vaccine Adjuvants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Vaccine Adjuvants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Vaccine Adjuvants Industry Trends Table 2. Vaccine Adjuvants Industry Drivers Table 3. Vaccine Adjuvants Industry Opportunities and Challenges Table 4. Vaccine Adjuvants Industry Restraints Table 5. Global Vaccine Adjuvants Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Vaccine Adjuvants Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Vaccine Adjuvants Sales by Manufacturers (MT) & (2021-2026) Table 8. Global Vaccine Adjuvants Sales Market Share by Manufacturers Table 9. Global Vaccine Adjuvants Average Sales Price (USD/Kg) of Manufacturers (2021-2026) Table 10. Global Vaccine Adjuvants Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Vaccine Adjuvants Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Vaccine Adjuvants Manufacturers, Product Type & Application Table 13. Global Vaccine Adjuvants Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Vaccine Adjuvants by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Aluminum Adjuvant Table 17. Major Manufacturers of Emulsions Adjuvant Table 18. Major Manufacturers of Others Table 19. Global Vaccine Adjuvants Sales by Type 2021 VS 2025 VS 2032 (MT) Table 20. Global Vaccine Adjuvants Sales by Type (2021-2026) & (MT) Table 21. Global Vaccine Adjuvants Sales by Type (2027-2032) & (MT) Table 22. Global Vaccine Adjuvants Sales Market Share by Type (2021-2026) Table 23. Global Vaccine Adjuvants Sales Market Share by Type (2027-2032) Table 24. Global Vaccine Adjuvants Revenue by Type 2021 VS 2025 VS 2032 (MT) Table 25. Global Vaccine Adjuvants Revenue by Type (2021-2026) & (MT) Table 26. Global Vaccine Adjuvants Revenue by Type (2027-2032) & (MT) Table 27. Global Vaccine Adjuvants Revenue Market Share by Type (2021-2026) Table 28. Global Vaccine Adjuvants Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Human Vaccine Table 30. Major Manufacturers of Veterinary Vaccine Table 31. Global Vaccine Adjuvants Sales by Application 2021 VS 2025 VS 2032 (MT) Table 32. Global Vaccine Adjuvants Sales by Application (2021-2026) & (MT) Table 33. Global Vaccine Adjuvants Sales by Application (2027-2032) & (MT) Table 34. Global Vaccine Adjuvants Sales Market Share by Application (2021-2026) Table 35. Global Vaccine Adjuvants Sales Market Share by Application (2027-2032) Table 36. Global Vaccine Adjuvants Revenue by Application 2021 VS 2025 VS 2032 (MT) Table 37. Global Vaccine Adjuvants Revenue by Application (2021-2026) & (MT) Table 38. Global Vaccine Adjuvants Revenue by Application (2027-2032) & (MT) Table 39. Global Vaccine Adjuvants Revenue Market Share by Application (2021-2026) Table 40. Global Vaccine Adjuvants Revenue Market Share by Application (2027-2032) Table 41. Global Vaccine Adjuvants Sales by Region: 2021 VS 2025 VS 2032 (MT) Table 42. Global Vaccine Adjuvants Sales by Region (2021-2026) & (MT) Table 43. Global Vaccine Adjuvants Sales Market Share by Region (2021-2026) Table 44. Global Vaccine Adjuvants Sales Forecasted by Region (2027-2032) & (MT) Table 45. Global Vaccine Adjuvants Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Vaccine Adjuvants Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (MT) Table 47. North America Vaccine Adjuvants Sales by Country (2021-2026) & (MT) Table 48. North America Vaccine Adjuvants Sales by Country (2027-2032) & (MT) Table 49. Europe Vaccine Adjuvants Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (MT) Table 50. Europe Vaccine Adjuvants Sales by Country (2021-2026) & (MT) Table 51. Europe Vaccine Adjuvants Sales by Country (2027-2032) & (MT) Table 52. Asia Pacific Vaccine Adjuvants Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (MT) Table 53. Asia Pacific Vaccine Adjuvants Sales by Country (2021-2026) & (MT) Table 54. Asia Pacific Vaccine Adjuvants Sales by Country (2027-2032) & (MT) Table 55. South America, Middle East and Africa Vaccine Adjuvants Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (MT) Table 56. South America, Middle East and Africa Vaccine Adjuvants Sales by Country (2021-2026) & (MT) Table 57. South America, Middle East and Africa Vaccine Adjuvants Sales by Country (2027-2032) & (MT) Table 58. Global Vaccine Adjuvants Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Vaccine Adjuvants Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Vaccine Adjuvants Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Vaccine Adjuvants Revenue Market Share by Region (2021-2026) Table 62. Global Vaccine Adjuvants Revenue Market Share by Region (2027-2032) Table 63. GSK Company Information Table 64. GSK Business Overview Table 65. GSK Vaccine Adjuvants Sales (MT), Price (USD/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. GSK Vaccine Adjuvants Product Portfolio Table 67. GSK Recent Development Table 68. CSL Limited Company Information Table 69. CSL Limited Business Overview Table 70. CSL Limited Vaccine Adjuvants Sales (MT), Price (USD/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. CSL Limited Vaccine Adjuvants Product Portfolio Table 72. CSL Limited Recent Development Table 73. Croda Company Information Table 74. Croda Business Overview Table 75. Croda Vaccine Adjuvants Sales (MT), Price (USD/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Croda Vaccine Adjuvants Product Portfolio Table 77. Croda Recent Development Table 78. SEPPIC Company Information Table 79. SEPPIC Business Overview Table 80. SEPPIC Vaccine Adjuvants Sales (MT), Price (USD/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. SEPPIC Vaccine Adjuvants Product Portfolio Table 82. SEPPIC Recent Development Table 83. Novavax Company Information Table 84. Novavax Business Overview Table 85. Novavax Vaccine Adjuvants Sales (MT), Price (USD/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Novavax Vaccine Adjuvants Product Portfolio Table 87. Novavax Recent Development Table 88. SPI Pharma Company Information Table 89. SPI Pharma Business Overview Table 90. SPI Pharma Vaccine Adjuvants Sales (MT), Price (USD/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. SPI Pharma Vaccine Adjuvants Product Portfolio Table 92. SPI Pharma Recent Development Table 93. Phibro Company Information Table 94. Phibro Business Overview Table 95. Phibro Vaccine Adjuvants Sales (MT), Price (USD/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Phibro Vaccine Adjuvants Product Portfolio Table 97. Phibro Recent Development Table 98. SDA BIO Company Information Table 99. SDA BIO Business Overview Table 100. SDA BIO Vaccine Adjuvants Sales (MT), Price (USD/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. SDA BIO Vaccine Adjuvants Product Portfolio Table 102. SDA BIO Recent Development Table 103. Invivogen Company Information Table 104. Invivogen Business Overview Table 105. Invivogen Vaccine Adjuvants Sales (MT), Price (USD/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Invivogen Vaccine Adjuvants Product Portfolio Table 107. Invivogen Recent Development Table 108. Tj Kaiwei Company Information Table 109. Tj Kaiwei Business Overview Table 110. Tj Kaiwei Vaccine Adjuvants Sales (MT), Price (USD/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Tj Kaiwei Vaccine Adjuvants Product Portfolio Table 112. Tj Kaiwei Recent Development Table 113. OZ Biosciences Company Information Table 114. OZ Biosciences Business Overview Table 115. OZ Biosciences Vaccine Adjuvants Sales (MT), Price (USD/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. OZ Biosciences Vaccine Adjuvants Product Portfolio Table 117. OZ Biosciences Recent Development Table 118. Brenntag Biosector Company Information Table 119. Brenntag Biosector Business Overview Table 120. Brenntag Biosector Vaccine Adjuvants Sales (MT), Price (USD/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Brenntag Biosector Vaccine Adjuvants Product Portfolio Table 122. Brenntag Biosector Recent Development Table 123. MVP Laboratories Company Information Table 124. MVP Laboratories Business Overview Table 125. MVP Laboratories Vaccine Adjuvants Sales (MT), Price (USD/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. MVP Laboratories Vaccine Adjuvants Product Portfolio Table 127. MVP Laboratories Recent Development Table 128. Zhuoyue Company Information Table 129. Zhuoyue Business Overview Table 130. Zhuoyue Vaccine Adjuvants Sales (MT), Price (USD/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Zhuoyue Vaccine Adjuvants Product Portfolio Table 132. Zhuoyue Recent Development Table 133. Aphios Company Information Table 134. Aphios Business Overview Table 135. Aphios Vaccine Adjuvants Sales (MT), Price (USD/Kg), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Aphios Vaccine Adjuvants Product Portfolio Table 137. Aphios Recent Development Table 138. Key Raw Materials Table 139. Raw Materials Key Suppliers Table 140. Vaccine Adjuvants Distributors List Table 141. Vaccine Adjuvants Customers List Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Vaccine Adjuvants Product Image Figure 2. Global Vaccine Adjuvants Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaccine Adjuvants Market Size (2021-2032) & (US$ Million) Figure 4. Global Vaccine Adjuvants Sales (2021-2032) & (MT) Figure 5. Global Vaccine Adjuvants Average Price (USD/Kg) & (2021-2032) Figure 6. Global Top 5 and 10 Vaccine Adjuvants Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Aluminum Adjuvant Image Figure 9. Emulsions Adjuvant Image Figure 10. Others Image Figure 11. Global Vaccine Adjuvants Sales by Type (2021 VS 2025 VS 2032) & (MT) Figure 12. Global Vaccine Adjuvants Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Vaccine Adjuvants Sales Market Share by Type (2021-2032) Figure 14. Global Vaccine Adjuvants Revenue by Type (2021 VS 2025 VS 2032) & (MT) Figure 15. Global Vaccine Adjuvants Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Vaccine Adjuvants Revenue Market Share by Type (2021-2032) Figure 17. Human Vaccine Image Figure 18. Veterinary Vaccine Image Figure 19. Global Vaccine Adjuvants Sales by Application (2021 VS 2025 VS 2032) & (MT) Figure 20. Global Vaccine Adjuvants Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Vaccine Adjuvants Sales Market Share by Application (2021-2032) Figure 22. Global Vaccine Adjuvants Revenue by Application (2021 VS 2025 VS 2032) & (MT) Figure 23. Global Vaccine Adjuvants Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Vaccine Adjuvants Revenue Market Share by Application (2021-2032) Figure 25. North America Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 26. North America Vaccine Adjuvants Sales Market Share by Country (2021-2032) Figure 27. U.S. Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 28. Canada Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 29. Mexico Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 30. Europe Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 31. Europe Vaccine Adjuvants Sales Market Share by Country (2021-2032) Figure 32. Germany Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 33. France Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 34. U.K. Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 35. Italy Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 36. Netherlands Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 37. Asia Pacific Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 38. Asia Pacific Vaccine Adjuvants Sales Market Share by Country (2021-2032) Figure 39. China Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 40. Japan Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 41. South Korea Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 42. Southeast Asia Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 43. India Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 44. Australia Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 45. South America, Middle East and Africa Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 46. South America, Middle East and Africa Vaccine Adjuvants Sales Market Share by Country (2021-2032) Figure 47. Brazil Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 48. South Africa Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 49. Saudi Arabia Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 50. Turkey Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 51. Argentina Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 52. UAE Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 53. Egypt Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 54. Chile Vaccine Adjuvants Sales and Growth Rate (2021-2032) & (MT) Figure 55. Global Vaccine Adjuvants Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Vaccine Adjuvants Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Vaccine Adjuvants Revenue (2021-2032) & (US$ Million) Figure 58. North America Vaccine Adjuvants Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Vaccine Adjuvants Revenue (2021-2032) & (US$ Million) Figure 60. Europe Vaccine Adjuvants Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Vaccine Adjuvants Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Vaccine Adjuvants Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Vaccine Adjuvants Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Vaccine Adjuvants Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Vaccine Adjuvants Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Vaccine Adjuvants Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Aluminum Adjuvant
  • Emulsions Adjuvant
  • Others
Applications
  • Human Vaccine
  • Veterinary Vaccine
Companies covered
  • GSK
  • CSL Limited
  • Croda
  • SEPPIC
  • Novavax
  • SPI Pharma
  • Phibro
  • SDA BIO
  • Invivogen
  • Tj Kaiwei
  • OZ Biosciences
  • Brenntag Biosector
  • MVP Laboratories
  • Zhuoyue
  • Aphios

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vaccine Adjuvants Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vaccine Adjuvants Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Vaccine Adjuvants Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Vaccine Adjuvants Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Vaccine Adjuvants Market Dynamics
  1. 2.1 Vaccine Adjuvants Industry Trends
  2. 2.2 Vaccine Adjuvants Industry Drivers
  3. 2.3 Vaccine Adjuvants Industry Opportunities and Challenges
  4. 2.4 Vaccine Adjuvants Industry Restraints
3 Vaccine Adjuvants Market by Manufacturers
  1. 3.1 Global Vaccine Adjuvants Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Vaccine Adjuvants Sales by Manufacturers (2021-2026)
  3. 3.3 Global Vaccine Adjuvants Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Vaccine Adjuvants Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vaccine Adjuvants Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Vaccine Adjuvants Manufacturers, Product Type & Application
  7. 3.7 Global Vaccine Adjuvants Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vaccine Adjuvants Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vaccine Adjuvants Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vaccine Adjuvants Tier 1, Tier 2, and Tier 3
4 Vaccine Adjuvants Market by Type
  1. 4.1 Vaccine Adjuvants Type Introduction
  2. 4.1.1 Aluminum Adjuvant
  3. 4.1.2 Emulsions Adjuvant
  4. 4.1.3 Others
  5. 4.2 Global Vaccine Adjuvants Sales by Type
  6. 4.2.1 Global Vaccine Adjuvants Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Vaccine Adjuvants Sales by Type (2021-2032)
  8. 4.2.3 Global Vaccine Adjuvants Sales Market Share by Type (2021-2032)
  9. 4.3 Global Vaccine Adjuvants Revenue by Type
  10. 4.3.1 Global Vaccine Adjuvants Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Vaccine Adjuvants Revenue by Type (2021-2032)
  12. 4.3.3 Global Vaccine Adjuvants Revenue Market Share by Type (2021-2032)
5 Vaccine Adjuvants Market by Application
  1. 5.1 Vaccine Adjuvants Application Introduction
  2. 5.1.1 Human Vaccine
  3. 5.1.2 Veterinary Vaccine
  4. 5.2 Global Vaccine Adjuvants Sales by Application
  5. 5.2.1 Global Vaccine Adjuvants Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Vaccine Adjuvants Sales by Application (2021-2032)
  7. 5.2.3 Global Vaccine Adjuvants Sales Market Share by Application (2021-2032)
  8. 5.3 Global Vaccine Adjuvants Revenue by Application
  9. 5.3.1 Global Vaccine Adjuvants Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Vaccine Adjuvants Revenue by Application (2021-2032)
  11. 5.3.3 Global Vaccine Adjuvants Revenue Market Share by Application (2021-2032)
6 Global Vaccine Adjuvants Sales by Region
  1. 6.1 Global Vaccine Adjuvants Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vaccine Adjuvants Sales by Region (2021-2032)
  3. 6.2.1 Global Vaccine Adjuvants Sales by Region (2021-2026)
  4. 6.2.2 Global Vaccine Adjuvants Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vaccine Adjuvants Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Vaccine Adjuvants Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Vaccine Adjuvants Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Vaccine Adjuvants Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Vaccine Adjuvants Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Vaccine Adjuvants Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Vaccine Adjuvants Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Vaccine Adjuvants Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Vaccine Adjuvants Revenue by Region
  1. 7.1 Global Vaccine Adjuvants Revenue by Region
  2. 7.1.1 Global Vaccine Adjuvants Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Vaccine Adjuvants Revenue by Region (2021-2026)
  4. 7.1.3 Global Vaccine Adjuvants Revenue by Region (2027-2032)
  5. 7.1.4 Global Vaccine Adjuvants Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Vaccine Adjuvants Revenue (2021-2032)
  8. 7.2.2 North America Vaccine Adjuvants Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Vaccine Adjuvants Revenue (2021-2032)
  11. 7.3.2 Europe Vaccine Adjuvants Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Vaccine Adjuvants Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Vaccine Adjuvants Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Vaccine Adjuvants Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Vaccine Adjuvants Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Vaccine Adjuvants Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 CSL Limited
  8. 8.2.1 CSL Limited Company Information
  9. 8.2.2 CSL Limited Business Overview
  10. 8.2.3 CSL Limited Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CSL Limited Vaccine Adjuvants Product Portfolio
  12. 8.2.5 CSL Limited Recent Developments
  13. 8.3 Croda
  14. 8.3.1 Croda Company Information
  15. 8.3.2 Croda Business Overview
  16. 8.3.3 Croda Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Croda Vaccine Adjuvants Product Portfolio
  18. 8.3.5 Croda Recent Developments
  19. 8.4 SEPPIC
  20. 8.4.1 SEPPIC Company Information
  21. 8.4.2 SEPPIC Business Overview
  22. 8.4.3 SEPPIC Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 SEPPIC Vaccine Adjuvants Product Portfolio
  24. 8.4.5 SEPPIC Recent Developments
  25. 8.5 Novavax
  26. 8.5.1 Novavax Company Information
  27. 8.5.2 Novavax Business Overview
  28. 8.5.3 Novavax Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novavax Vaccine Adjuvants Product Portfolio
  30. 8.5.5 Novavax Recent Developments
  31. 8.6 SPI Pharma
  32. 8.6.1 SPI Pharma Company Information
  33. 8.6.2 SPI Pharma Business Overview
  34. 8.6.3 SPI Pharma Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 SPI Pharma Vaccine Adjuvants Product Portfolio
  36. 8.6.5 SPI Pharma Recent Developments
  37. 8.7 Phibro
  38. 8.7.1 Phibro Company Information
  39. 8.7.2 Phibro Business Overview
  40. 8.7.3 Phibro Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Phibro Vaccine Adjuvants Product Portfolio
  42. 8.7.5 Phibro Recent Developments
  43. 8.8 SDA BIO
  44. 8.8.1 SDA BIO Company Information
  45. 8.8.2 SDA BIO Business Overview
  46. 8.8.3 SDA BIO Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 SDA BIO Vaccine Adjuvants Product Portfolio
  48. 8.8.5 SDA BIO Recent Developments
  49. 8.9 Invivogen
  50. 8.9.1 Invivogen Company Information
  51. 8.9.2 Invivogen Business Overview
  52. 8.9.3 Invivogen Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Invivogen Vaccine Adjuvants Product Portfolio
  54. 8.9.5 Invivogen Recent Developments
  55. 8.10 Tj Kaiwei
  56. 8.10.1 Tj Kaiwei Company Information
  57. 8.10.2 Tj Kaiwei Business Overview
  58. 8.10.3 Tj Kaiwei Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Tj Kaiwei Vaccine Adjuvants Product Portfolio
  60. 8.10.5 Tj Kaiwei Recent Developments
  61. 8.11 OZ Biosciences
  62. 8.11.1 OZ Biosciences Company Information
  63. 8.11.2 OZ Biosciences Business Overview
  64. 8.11.3 OZ Biosciences Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 OZ Biosciences Vaccine Adjuvants Product Portfolio
  66. 8.11.5 OZ Biosciences Recent Developments
  67. 8.12 Brenntag Biosector
  68. 8.12.1 Brenntag Biosector Company Information
  69. 8.12.2 Brenntag Biosector Business Overview
  70. 8.12.3 Brenntag Biosector Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Brenntag Biosector Vaccine Adjuvants Product Portfolio
  72. 8.12.5 Brenntag Biosector Recent Developments
  73. 8.13 MVP Laboratories
  74. 8.13.1 MVP Laboratories Company Information
  75. 8.13.2 MVP Laboratories Business Overview
  76. 8.13.3 MVP Laboratories Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 MVP Laboratories Vaccine Adjuvants Product Portfolio
  78. 8.13.5 MVP Laboratories Recent Developments
  79. 8.14 Zhuoyue
  80. 8.14.1 Zhuoyue Company Information
  81. 8.14.2 Zhuoyue Business Overview
  82. 8.14.3 Zhuoyue Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Zhuoyue Vaccine Adjuvants Product Portfolio
  84. 8.14.5 Zhuoyue Recent Developments
  85. 8.15 Aphios
  86. 8.15.1 Aphios Company Information
  87. 8.15.2 Aphios Business Overview
  88. 8.15.3 Aphios Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Aphios Vaccine Adjuvants Product Portfolio
  90. 8.15.5 Aphios Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vaccine Adjuvants Value Chain Analysis
  2. 9.1.1 Vaccine Adjuvants Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vaccine Adjuvants Production Mode & Process
  6. 9.2 Vaccine Adjuvants Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vaccine Adjuvants Distributors
  9. 9.2.3 Vaccine Adjuvants Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst